Analyst Notes Podcast: Prostate Cancer and PARP inhibitors

FirstWord's Duncan Emerton - Senior Director of Syndicated Insights and Analysis - and Sarah Harris - Senior Analyst - discuss some of the key findings from a forthcoming KOL Insight: Prostate Cancer report

New Report: KOL Insight - Prostate Cancer


Twelve North American and European KOLs’ weigh in on the near-term outlook for 5 marketed prostate cancer treatments and 14 more currently in the pipeline. Learn whether hormonal therapies will move into earlier settings, whether bone-targeted therapies will see wider use in combination, whether new immunotherapies will outperform first-generation predecessors, whether PARP inhibitors offer real hope for personalized medicine, and more

Click here for more information

To read more Analyst Notes articles, click here.